Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma

Trial Profile

Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Aldesleukin (Primary) ; Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms PROCLIVITY 02
  • Sponsors Prometheus Laboratories
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 16 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 29 Jan 2014 New source identified and integrated (Barbara Ann Karmanos Cancer Institute; 2013-095)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top